NVNO Stock Price, enVVeno Medical Quote, Chart

Market Summary

USD5.11-0.12

Market Closed

-2.29%

NVNO Stock Price

View Fullscreen

NVNO RSI Chart

NVNO Valuation

Market Cap

68.0M

Price/Earnings (Trailing)

-2.89

Price/Sales (Trailing)

342.82

Price/Free Cashflow

-3.6

NVNO Price/Sales (Trailing)

NVNO Profitability

Return on Equity

-50.9%

Return on Assets

-48.35%

Free Cashflow Yield

-27.76%

NVNO Fundamentals

NVNO Revenue

Revenue (TTM)

198.5K

Rev. Growth (Yr)

-57.32%

Rev. Growth (Qtr)

-23.86%

NVNO Earnings

Earnings (TTM)

-23.5M

Earnings Growth (Yr)

8.59%

Earnings Growth (Qtr)

-12.96%

Breaking Down NVNO Revenue

Last 7 days

10.6%

Last 30 days

-3.2%

Last 90 days

21.7%

Trailing 12 Months

21.7%

How does NVNO drawdown profile look like?

NVNO Financial Health

Current Ratio

34.23

NVNO Investor Care

Shares Dilution (1Y)

40.59%

Diluted EPS (TTM)

-1.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	238.0K	240.0K	209.0K	198.5K
2022	20.0K	54.0K	122.0K	161.0K
2021	3.0K	10.0K	15.0K	0
2019	186.7K	103.4K	61.7K	31.2K
2018	363.2K	304.3K	245.4K	186.6K
2017	0	0	0	422.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of enVVeno Medical Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	alavi hamed	sold	-51,837	6.22	-8,334	chief technology officer
Mar 13, 2024	alavi hamed	acquired	29,919	3.59	8,334	chief technology officer
Sep 13, 2022	jenusaitis matthew	acquired	-	-	1,041	-
Sep 13, 2022	gray robert	acquired	-	-	1,041	-
Aug 16, 2022	duhay francis	bought	47,591	6.14	7,751	-
Jun 30, 2022	shrivastava sanjay	bought	3,850	3.85	1,000	-
Jun 27, 2022	berman robert andrew	bought	9,500	3.8	2,500	chief executive officer
Nov 30, 2021	berman robert andrew	acquired	-	-	200,000	chief executive officer
Nov 30, 2021	glickman marc h.	acquired	-	-	100,000	svp & chief medical officer
Nov 30, 2021	glynn craig	acquired	-	-	50,000	chief financial officer

Which funds bought or sold NVNO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Rosalind Advisors, Inc.	sold off	-100	-1,604,150	-	-%
Apr 22, 2024	ARTHUR M. COHEN & ASSOCIATES, LLC	sold off	-100	-71,960	-	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-16,848	-	-%
Apr 19, 2024	Westside Investment Management, Inc.	new	-	20,400	20,400	-%
Apr 12, 2024	Fermata Advisors, LLC	added	42.1	42,286	126,197	0.03%
Mar 18, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	added	282	3,127,790	4,309,170	0.27%
Mar 11, 2024	VANGUARD GROUP INC	added	0.18	-80,824	1,729,120	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	reduced	-20.25	-1,009,070	3,203,840	0.07%
Feb 15, 2024	Nantahala Capital Management, LLC	new	-	7,260,960	7,260,960	0.22%
Feb 14, 2024	UBS OCONNOR LLC	added	4.42	-5,177	1,214,620	0.09%

Are Funds Buying or Selling NVNO?

Are funds buying NVNO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVNO

No. of Funds

Unveiling enVVeno Medical Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2024	perceptive advisors llc	9.9%	1,394,716	SC 13G/A
Feb 14, 2024	perceptive advisors llc	9.9%	1,394,716	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	1,399,588	SC 13G
Feb 14, 2023	perceptive advisors llc	9.9%	937,515	SC 13G/A

Recent SEC filings of enVVeno Medical Corporation

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	8-K	Current Report
Mar 15, 2024	4	Insider Trading
Mar 06, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report
Feb 23, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to enVVeno Medical Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

enVVeno Medical Corporation News

Latest updates

enVVeno Medical Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2021Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	-23.9%	34.00	44.00	39.00	82.00	44.00	75.00	37.00	5.00	5.00	7.00	3.00	-	-	-	31.00	30.00	42.00	83.00	31.00	29.00	28.00
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.00	30.00	42.00	83.00	-	-	-105
S&GA Expenses	29.3%	3,300	2,551	2,600	3,202	3,663	3,659	3,913	3,783	1,482	1,296	1,176	922	1,157	1,532	1,301	1,217	1,105	2,915	1,247	-	-
R&D Expenses	6.5%	2,979	2,798	4,214	3,595	2,797	2,492	3,073	1,552	1,225	1,090	1,632	788	677	428	313	293	425	280	240	-	-
Interest Expenses	-	-	-	39.00	45.00	94.00	25.00	37.00	5.00	5.00	-6.70	3.00	-8.23	-19.14	-13.93	-8.61	-17.28	-6.98	112	210	-	-
Net Income	-13.0%	-5,649	-5,001	-6,474	-6,392	-6,180	-6,097	-7,062	-5,330	-2,389	-2,378	-2,773	-2,290	-1,814	-1,946	-1,573	-1,781	-1,468	-5,045	-4,747	-	-
Net Income Margin	-3.0%	-118.47*	-115.06*	-199.94*	-287.90*	-465.45*	-879.46*	-760.78*	-610.86*	-381.33*	-368.08*	-344.04*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-18.1%	-4,977	-4,216	-4,584	-5,114	-3,865	-4,497	-3,982	-3,390	-2,385	-2,798	-3,866	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	73.1%	48,635	28,094	32,086	36,613	41,661	45,456	49,932	54,224	57,699	59,172	42,352	45,055	10,538	7,043	3,733	2,770	3,434	5,751	7,253	5,488	3,559
Current Assets	79.0%	46,923	26,217	30,108	34,519	39,436	40,708	37,760	51,650	55,040	58,207	41,439	44,166	9,569	5,978	1,785	840	1,424	3,060	4,630	2,946	2,837
Cash Equivalents	-26.8%	3,620	4,946	4,700	2,273	4,555	2,895	9,070	51,338	54,728	57,897	41,039	43,837	9,335	5,629	1,564	720	1,307	2,943	4,465	2,753	2,741
Net PPE	-13.2%	334	385	438	472	521	566	606	635	618	599	490	395	399	426	427	330	344	350	194	25.00	26.00
Liabilities	-23.4%	2,435	3,179	3,274	2,484	2,932	2,785	3,374	2,907	3,295	1,118	1,478	2,043	3,440	2,248	3,364	2,784	2,444	2,667	2,601	2,623	1,523
Current Liabilities	-32.5%	1,371	2,031	2,067	1,167	1,530	1,304	1,816	1,270	1,580	1,118	1,393	1,874	3,186	1,915	2,953	2,253	1,876	2,016	1,883	1,839	1,523
Shareholder's Equity	85.4%	46,200	24,915	28,812	34,129	38,729	42,671	46,558	51,317	54,404	58,055	40,874	43,012	7,098	4,795	369	-	990	3,084	4,652	2,865	2,036
Retained Earnings	-4.5%	-130,036	-124,387	-119,386	-112,912	-106,520	-100,340	-94,243	-87,181	-81,851	-72,863	-70,474	-68,096	-65,323	-60,949	-58,974	-57,347	-56,187	-53,897	-52,082	-50,136	-48,562
Additional Paid-In Capital	18.0%	176,236	149,302	148,198	147,041	145,249	143,011	140,801	138,498	136,255	130,918	111,348	111,108	72,421	65,744	59,344	57,333	57,178	56,981	56,734	53,001	50,599
Shares Outstanding	40.6%	13,317	9,472	9,472	9,472	9,472	11,229	11,229	11,229	9,470	9,180	8,514	8,508	2,542	-	-	-	-	-	-	-	-
Float	-	-	-	29,200	-	-	-	35,800	-	-	-	58,500	-	-	-	9,244	-	-	-	18,639	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-18.0%	-4,973	-4,213	-4,563	-5,109	-3,856	-4,483	-3,959	-3,321	-3,102	-2,233	-2,671	-3,842	-2,613	-2,591	-1,319	-1,152	-1,623	-1,350	-1,429	-1,493	-1,444
Share Based Compensation	3.7%	1,144	1,103	1,157	1,792	2,238	2,210	2,303	2,243	5,343	325	202	129	518	194	38.00	131	-	194	447	104	906
Cashflow From Investing	-598.2%	-22,144	4,445	7,004	2,827	5,516	-1,692	-38,309	-69.00	-65.00	-152	-127	-24.00	-27.54	-24.96	-122	-5.31	-12.96	-171	-177	-1.80	-4.10
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-4.00	19,243	-	38,368	6,347	5,872	2,286	570	-	-	3,320	2,317	-

NVNO Income Statement

2023-12-31

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Research and development expenses	$ 13,583	$ 9,914
Selling, general and administrative expenses	11,655	15,018
Loss from Operations	(25,238)	(24,932)
Other Income:
Realized gain from sales of trading securities	1,074	53
Unrealized gain from trading securities	468	49
Interest income	180	161
Total Other Income	1,722	263
Net Loss	$ (23,516)	$ (24,669)
Net Loss Per Basic Common Share:	$ (1.91)	$ (2.20)
Net Loss Per Diluted Common Share:	$ (1.91)	$ (2.20)
Weighted Average Number of Common Shares Outstanding:
Basic	12,301	11,230
Diluted	12,301	11,230

NVNO Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 3,620	$ 4,555
Short-term investments	42,792	34,489
Prepaid expenses and other current assets	511	392
Total Current Assets	46,923	39,436
Property and equipment, net	334	521
Operating lease right-of-use assets, net	1,347	1,673
Security deposits and other assets	31	31
Total Assets	48,635	41,661
Current Liabilities:
Accounts payable, accrued expenses and other current liabilities	1,033	1,216
Current portion of operating lease liabilities	338	314
Total Current Liabilities	1,371	1,530
Long-term operating lease liabilities	1,064	1,402
Total Liabilities	2,435	2,932
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock, par value $0.00001, 10,000 shares authorized: no shares issued or outstanding
Common stock, par value $0.00001, 250,000 shares authorized, 13,317 and 9,472 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Additional paid-in capital	176,236	145,249
Accumulated deficit	(130,036)	(106,520)
Total Stockholders’ Equity	46,200	38,729
Total Liabilities and Stockholders’ Equity	$ 48,635	$ 41,661

About enVVeno Medical Corporation

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

CEO	Mr. Robert A. Berman
WEBSITE	envveno.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	30

enVVeno Medical Corporation Frequently Asked Questions

What is the ticker symbol for enVVeno Medical Corporation? What does NVNO stand for in stocks?

NVNO is the stock ticker symbol of enVVeno Medical Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of enVVeno Medical Corporation (NVNO)?

As of Fri Apr 26 2024, market cap of enVVeno Medical Corporation is 68.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVNO stock?

You can check NVNO's fair value in chart for subscribers.

What is the fair value of NVNO stock?

You can check NVNO's fair value in chart for subscribers. The fair value of enVVeno Medical Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of enVVeno Medical Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVNO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is enVVeno Medical Corporation a good stock to buy?

The fair value guage provides a quick view whether NVNO is over valued or under valued. Whether enVVeno Medical Corporation is cheap or expensive depends on the assumptions which impact enVVeno Medical Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVNO.

What is enVVeno Medical Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, NVNO's PE ratio (Price to Earnings) is -2.89 and Price to Sales (PS) ratio is 342.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVNO PE ratio will change depending on the future growth rate expectations of investors.